Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Califf Expected To Ace Senate Panel Vote, As He Ups Emphasis On Safety Surveillance

This article was originally published in The Gray Sheet

Executive Summary

The Senate Health, Education, Labor and Pensions Committee plans a confirmation vote on Robert Califf Jan. 12 to become the next FDA commissioner. Public health researchers and Sens. Sanders and Warren have argued that the long-time academic research leader's ties to industry are too close. Meanwhile, Califf recently has emphasized his focus on strengthening postmarket safety oversight.


Related Content

Califf Sets Departure From US FDA; Ostroff May Become Interim Leader
FDA Drafts Plan To Publicize 'Emerging Signals' Of Device Risks
Postmarket Device Surveillance Reforms Raised At Califf Confirmation Hearing
Califf Supports Combo Products Pathway At Confirmation Hearing
Consumer Groups Oppose Califf To Head FDA, Citing Industry Ties